AndreaBozzo/ceres-open-data-index huggingface dataset:
Comparison of the 2021-2022 and 2022-2023 State Prevalence Tables

Examine the change in state estimates between 2021-2022 and 2022-2023 from the National Surveys on Drug Use and Health (NSDUH) and determine if they were statistically significant using p-values. The tables accompany the2022-2023 NSDUH State Estimates of Substance Use and Mental Health, and include estimates for both time periods, as well as a p-value for determining statistical significance. There is also a guide to the methodology used to calculate the p-values.The tables are available in PDF or HTML format.
Herpes simplex virus bullous keratitis misdiagnosed as a case of pseudophakic bullous keratopathy with secondary glaucoma: an unusual presentation

Purpose
          To report an unusual case of herpetic bullous keratitis misdiagnosed as a case of pseudophakic bullous keratopathy with secondary glaucoma.
        
        
          Results
          A retrospective analysis of the case record of a 60-year-old man who had earlier undergone bilateral cataract surgery, was done. He presented with a complaint of decrease in vision in the right eye of 20 days duration. On examination, cornea showed epithelial bullae all over the surface with stromal and epithelial edema. Intraocular pressure was 30 mm of Hg in RE. He was treated with anti-glaucoma medications. Two dendritic lesions were seen in the cornea during a subsequent visit four days later. Virological investigations confirmed a diagnosis of Herpes simplex keratitis. He was treated with topical acyclovir.
        
        
          Conclusions
          This case highlights the fact that herpes simplex keratitis can present initially as a more diffuse corneal stromal and epithelial edema with epithelial bullae mimicking bullous keratopathy. Herpetic bullous keratitis, although unusual, should be considered in the differential diagnosis under such circumstances.
2012 Uniform Reporting System (URS) Tables for Arizona

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Accessing and distributing EMBL data using CORBA (common object request broker architecture)

Background:
          The EMBL Nucleotide Sequence Database is a comprehensive database of DNA and RNA sequences and related information traditionally made available in flat-file format. Queries through tools such as SRS (Sequence Retrieval System) also return data in flat-file format. Flat files have a number of shortcomings, however, and the resources therefore currently lack a flexible environment to meet individual researchers' needs. The Object Management Group's common object request broker architecture (CORBA) is an industry standard that provides platform-independent programming interfaces and models for portable distributed object-oriented computing applications. Its independence from programming languages, computing platforms and network protocols makes it attractive for developing new applications for querying and distributing biological data.
        
        
          Results:
          A CORBA infrastructure developed by EMBL-EBI provides an efficient means of accessing and distributing EMBL data. The EMBL object model is defined such that it provides a basis for specifying interfaces in interface definition language (IDL) and thus for developing the CORBA servers. The mapping from the object model to the relational schema in the underlying Oracle database uses the facilities provided by PersistenceTM, an object/relational tool. The techniques of developing loaders and 'live object caching' with persistent objects achieve a smart live object cache where objects are created on demand. The objects are managed by an evictor pattern mechanism.
        
        
          Conclusions:
          The CORBA interfaces to the EMBL database address some of the problems of traditional flat-file formats and provide an efficient means for accessing and distributing EMBL data. CORBA also provides a flexible environment for users to develop their applications by building clients to our CORBA servers, which can be integrated into existing systems.
COVID-19 State Profile Report - Colorado

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
The Immunology Database and Analysis Portal (ImmPort)

<p>The ImmPort system serves as a long-term, sustainable archive of immunology research data generated by investigators mainly funded through the NIAID/DAIT. The core component of the ImmPort system is an extensive data warehouse containing an integration of experimental data and clinical trial data. The ImmPort system also provides data analysis tools and an immunology-focused ontology. The analytical tools created and integrated as part of the ImmPort system are available to any researcher within ImmPort after registration and approval by DAIT. Additionally, the data provided mainly by NIAID/DAIT funded researchers in ImmPort will be available to all registered users after the appropriate embargo time.</p>
Restructured BETOS Classification System

The Restructured BETOS Classification System (RBCS) dataset is a taxonomy that allows researchers to group healthcare service codes for Medicare Part B services (i.e., HCPCS codes) into clinically meaningful categories and subcategories. It is based on the original Berenson-Eggers Type of Service (BETOS) classification created in the 1980s, and includes notable updates such as Part B non-physician services. The RBCS will undergo annual updates by a technical expert panel of researchers and clinicians.
Compound 528012: 4-Penten-2-yl 4-nitrobenzoate

Chemical compound data from PubChem database. IUPAC Name: pent-4-en-2-yl 4-nitrobenzoate. Molecular Formula: C12H13NO4. Molecular Weight: 235.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525582: N,N-Dimethyl-N'-(3-nitrophenyl)-benzamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-(3-nitrophenyl)benzenecarboximidamide. Molecular Formula: C15H15N3O2. Molecular Weight: 269.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Variations in chemoprophylaxis for meningococcal disease: a retrospective case note review, analysis of routine prescribing data and questionnaire of general practitioners

Background
          Invasive meningococcal disease is a significant cause of mortality and morbidity in the UK. Administration of chemoprophylaxis to close contacts reduces the risk of a secondary case. However, unnecessary chemoprophylaxis may be associated with adverse reactions, increased antibiotic resistance and removal of organisms, such as Neisseria lactamica, which help to protect against meningococcal disease. Limited evidence exists to suggest that overuse of chemoprophylaxis may occur. This study aimed to evaluate prescribing of chemoprophylaxis for contacts of meningococcal disease by general practitioners and hospital staff.
        
        
          Methods
          Retrospective case note review of cases of meningococcal disease was conducted in one health district from 1st September 1997 to 31st August 1999. Routine hospital and general practitioner prescribing data was searched for chemoprophylactic prescriptions of rifampicin and ciprofloxacin. A questionnaire of general practitioners was undertaken to obtain more detailed information.
        
        
          Results
          Prescribing by hospital doctors was in line with recommendations by the Consultant for Communicable Disease Control. General practitioners prescribed 118% more chemoprophylaxis than was recommended. Size of practice and training status did not affect the level of additional prescribing, but there were significant differences by geographical area. The highest levels of prescribing occurred in areas with high disease rates and associated publicity. However, some true close contacts did not appear to receive prophylaxis.
        
        
          Conclusions
          Receipt of chemoprophylaxis is affected by a series of patient, doctor and community interactions. High publicity appears to increase demand for prophylaxis. Some true contacts do not receive appropriate chemoprophylaxis and are left at an unnecessarily increased risk.
Patent AT-E40168-T1: [Translated] METHOD AND SEALING DEVICE FOR SEALING A LID IN ITS POSITION.

1. Sealing device of a cover of a support body and a lid supported in the support body for sealing the lid in the wall region of its support and in the wall region of the support of the support body, wherein in these wall regions the lid and the support body lie against one another and are sealed by a soft seal, characterised in that in one part of the adjacently lying wall regions (6, 7) of the lid (1) and of the support body (2) a recess (10) is arranged which extends annularly along the wall regions and is filled with a flowable sealing composition as well as being connected with two openings (11, 12) arranged at a distance from one another and debouching on the outer side of the lid or of the support body.
Motor Vehicle Occupant Death Rate, by Age and Sex, 2012 & 2014, Region 3 - Philadelphia

Rate of deaths by age/gender (per 100,000 population) for motor vehicle occupants killed in crashes, 2012 & 2014. 2012 Source: Fatality Analysis Reporting System (FARS). 2014 Source: National Highway Traffic Safety Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File Note: Blank cells indicate data are suppressed. Fatality rates based on fewer than 20 deaths are suppressed.
Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (

Background:
          Differences in responses to bacterial surface lipopolysaccharides (LPSs) are apparent between and within mammalian species. It has been shown in mice that resistance to LPS is caused by defects in the Toll-like receptor 4 gene (Tlr4), the product of which is thought to bind LPS and mediate LPS signal transduction in immune system cells.
        
        
          Results:
          We have sequenced the Toll-like receptor 4 gene of humans (TLR4; 19.0 kilobases, kb) and mice (Tlr4; 91.7 kb), as well as the coding region and splice junctions of Tlr4 from 35 mouse (Mus musculus) strains, from the chimpanzee and from the baboon. No other discernible genes or regions of interspecies conservation lies close to Tlr4 and, in both humans and mice, flanking sequences and introns are rich in repeats of retroviral origin. Interstrain analyses reveal that Tlr4 is a polymorphic protein and that the extracellular domain is far more variable than the cytoplasmic domain, both among strains and among species. The cytoplasmic domain of the Tlr4 protein is highly variable at the carboxy-terminal end.
        
        
          Conclusions:
          We suggest that selective evolutionary pressure exerted by microbes expressing structurally distinguishable LPS molecules has produced the high level of variability in the Tlr4 extracellular domain. The highly variable carboxy-terminal region of the cytoplasmic domain is likely to determine the magnitude of the response to LPS within a species.
NNDSS - Table 1F. Brucellosis to Candida auris, clinical

NNDSS - Table 1F. Brucellosis to Candida auris, clinical - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Patent AT-E400595-T1: [Translated] LOW SOLVENT, OH-FUNCTIONAL DISPERSIONS II

A process for preparing copolymer dispersions that includes subjecting A) one or more vinyl monomer mixtures containing a) OH-free (meth)acrylic esters and/or vinylaromatics, b) hydroxy-functional vinyl monomers and/or hydroxy-functional (meth)acrylic esters, c) ionic and/or potentially ionic monomers capable of free-radical copolymerization, and d)optionally further monomers, other than the compounds of components a)-c), capable of free-radical copolymerization; to free-radical polymerization in the presence of e) compounds according to formula (I) where R<SUP>1 </SUP>is an aliphatic, araliphatic or aromatic radical having 1 to 18 carbon atoms, R<SUP>2 </SUP>is H or CH<SUB>3</SUB>, R<SUP>3</SUP>, R<SUP>4 </SUP>are identical or different aliphatc radicals having 1 to 7 carbon atoms and n is 1 to 4; and subsequently dispersing the resultant copolymer B) before or after addition of a neutralizing agent C) in water. The resulting dispersions can be used to coat substrates.
The promise of e-Health – a Canadian perspective

Canadians value their health care system above any other social program. Canada's system of health care faces significant financial and population pressures, relating to cost, access, quality, accountability, and the integration of information and communication technologies (ICTs). The health-system also faces certain unique challenges that include care delivery within a highly decentralised system of financing and accountability, and care delivery to a significant portion of the population sparsely distributed across a landmass of 10 million square kilometres, in areas of extreme climatic conditions. All of these challenges are significant catalysts in the development of technologies that aim to significantly mitigate or eliminate these selfsame challenges.
        The system is undergoing widespread review, nationally, and within each province and territory, where the bulk of care provision is financed and managed. The challenges are being addressed by national, regional and provincial initiatives in the public, private and not-for-profit sectors.
        The promise of e-Health lies in the manner and degree to which it can mitigate or resolve these challenges to the health system and build on advancements in ICTs supporting the development of a health infostructure. Canada is actively developing and implementing technological solutions to deliver health information and health care services across the country. These solutions, while exciting and promising, also present new challenges, particularly in regard to acceptable standards, choice of technologies, overcoming traditional jurisdictional boundaries, up-front investment, and privacy and confidentially.
        Many organisations and governments are working to address these challenges. The Canadian Institute for Health Information (CIHI) will play an increasingly significant role in these initiatives, as the management of health information becomes a more crucial factor in the successful delivery of health care services in the new millennium.
Genetic linkage and transmission disequilibrium of marker haplotypes at chromosome 1q41 in human systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies to a wide range of self-antigens. Recent genome screens have implicated numerous chromosomal regions as potential SLE susceptibility loci. Among these, the 1q41 locus is of particular interest, because evidence for linkage has been found in several independent SLE family collections. Additionally, the 1q41 locus appears to be syntenic with a susceptibility interval identified in the NZM2410 mouse model for SLE. Here, we report the results of genotyping of 11 microsatellite markers within the 1q41 region in 210 SLE sibpair and 122 SLE trio families. These data confirm the modest evidence for linkage at 1q41 in our family collection (LOD = 1.21 at marker D1S2616). Evidence for significant linkage disequilibrium in this interval was also found. Multiple markers in the region exhibit transmission disequilibrium, with the peak single marker multiallelic linkage disequilibrium noted at D1S490 (pedigree disequilibrium test [PDT] global P value = 0.0091). Two- and three-marker haplotypes from the 1q41 region similarly showed strong transmission distortion in the collection of 332 SLE families. The finding of linkage together with significant transmission disequilibrium provides strong evidence for a susceptibility locus at 1q41 in human SLE.
2012 Uniform Reporting System (URS) Tables for Republic of Marshall Islands

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 526711: Pentaethylene glycol, decyl ether, TMS

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-(2-decoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy-trimethylsilane. Molecular Formula: C23H50O6Si. Molecular Weight: 450.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
FY 2001 Children's Bureau Competitive Discretionary Grant Awards

This document provides a list of Children's Bureau discretionary grants and cooperative agreements awarded in fiscal year 2001:

2001A: Adoption Opportunities (approximately $3.1 million)

2001A.1 Achieving Increased Adoptive Placements For Children in Foster Care - $250,000 each year for 3 years

2001A.2 Field Initiated Demonstration Projects Advancing the State of the Art in the Adoption Field - $250,000 each year for 4 years

2001A.3 Quality Improvement Centers on Adoptionyear 1=$175,000, years 2,3,4 & 5=$500,000 per year

2001A.4 Evaluations of Existing Adoption Programs$100,000 each year for 3 years

2001B: Child Abuse and Neglect (approximately $3.8 million)

2001B.1 National Resource Center on Child Maltreatment$700,000 each year for two years

2001B.2 Investigator-Initiated Research Advancing the State of the Art in the Child Abuse and Neglect Field$250,000 each year for 3 years

2001B.3 Field-initiated Demonstration Projects Advancing the State of the Art in the Child Abuse and Neglect Field - $250,000 each year for 4 years

2001B.4 Quality Improvement Centers on Child Protective Services -year 1=$175,000, years 2,3,4 & 5= $500,000 per year

2001B.5 Evaluations of Existing Child Abuse and Neglect Prevention or Intervention Programs$100,000 each year for 3 years

2001C: Abandoned Infants (approximately $4.2 million)

2001C.1 Support for Previous Comprehensive Service Demonstration Projects$450,000 each year for 4 years

2001C.2 Support for New Comprehensive Service Demonstration Projects -$450,000 per year for 4 years

2001C.3 Family Support Services for Grandparents and Other Relatives Providing Caregiving for Children of Substance Abusing and HIV-Positive Women - $100,000 each year for 4 years

2001C.4 Recreational Services for Children Affected by HIV/AIDS - $100,000 each year for 4 years

2001D: Child Welfare (approximately $1.6 million)

2001D.1 Demonstration Sites: Building Analytical Capacity For Child Welfare Programs in State Systems - $250,000 each year for 3 years

2001D.2 Mentor Sites: Building Analytical Capacity For Child Welfare Programs in State Systems - $150,000 per year for 3 years

Metadata-only record linking to the original dataset. Open original dataset below.